CASE REPORT
Uterine sarcoma – time is worth its weight in gold
1
Department of Obstetrics and Gynaecology, District Public Hospital in Poznan, Poznan, Poland
2
Doctoral School, Poznan University of Medical Sciences, Poznan, Poland
3
Department of Gynaecological Oncology, Poznan University of Medical Sciences, Poznan, Poland
4
Department of Pathomorphology, District Public Hospital in Poznan, Poznan, Poland
5
Department of Gynaecological Endocrinology and Gynaecology, Jagiellonian University Medical College, Cracow, Poland
Submission date: 2022-04-30
Final revision date: 2022-07-14
Acceptance date: 2023-03-16
Publication date: 2023-04-28
Corresponding author
Robert Jach
Prof. Robert Jach Department of Gynaecological Endocrinology and Gynaecology Jagiellonian University Medical College Cracow, Poland
Prof. Robert Jach Department of Gynaecological Endocrinology and Gynaecology Jagiellonian University Medical College Cracow, Poland
Pol J Pathol 2023;74(1):59-62
KEYWORDS
TOPICS
ABSTRACT
Leiomyosarcoma is one of the most common types of soft tissue sarcoma in adults, and it can occur in almost any part of the body.
Uterine leiomyosarcoma constitutes 1% of all gynaecological tumours. Most diagnosed sarcomas are not even suspected before surgery. However, in recent years, awareness of their presence in society has increased.
Our case aims to draw attention to the need for better cooperation between pathologists and clinicians and reduce the time from suspicion of the disease to final diagnosis.
Uterine leiomyosarcoma constitutes 1% of all gynaecological tumours. Most diagnosed sarcomas are not even suspected before surgery. However, in recent years, awareness of their presence in society has increased.
Our case aims to draw attention to the need for better cooperation between pathologists and clinicians and reduce the time from suspicion of the disease to final diagnosis.
REFERENCES (7)
1.
Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma: a gynecologic oncology group study. Cancer 1993; 71: 1702-1709.
2.
Giuntoli RL, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecologic Oncology 2003; 89: 460-469.
3.
Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 2008; 112: 820-830.
4.
Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynecol Obst 2018; 143:51-58.
5.
Cornfeld D, Israel G, Martel M, et al. MRI appearance of mesenchymal tumors of the uterus. Eur J Radiol 2010; 74: 241-249.
6.
Lakhman Y, Veeraraghavan H, Chaim J, et al. Differentiation of uterine leiomyosarcoma from atypical leiomyoma: diagnostic accuracy of qualitative MR imaging features and feasibility of texture analysis. Eur Radiol 2017; 27: 2903-2915.
7.
George S, Barysauskas C, Serrano C, et al. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer 2014; 120: 3154-3158.
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
